Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in Advanced Solid Tumors
NCT02974738Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of belzutifan in solid tumor, clear cell renal cell carcinoma (ccRCC) and glioblastoma (GBM) (4 arms), sponsored by Merck & Co. Primary endpoint: Maximum Tolerated Dose at 3 weeks. Started Dec 2016; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
solid tumorclear cell renal cell carcinoma (ccRCC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02974738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974738.